January 2, 2019 08:17 AM ESTUpdated April 18, 10:42 AM

Did Moderna break the biotech IPO market?

Natalie Grover

Reporter

2018 ended replete with a record-breaking round of FDA approvals and IPO cash riches for the year. But that rapacious enthusiasm soured as December ravaged …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Did Moderna break the biotech IPO market?

Natalie Grover

Reporter

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA approves first drug to treat ultra-rare lipid storage disease

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA says Ozempic, Wegovy shortage is over

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Did Mod­er­na break the biotech IPO mar­ket?

Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Did Moderna break the biotech IPO market?